Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 25, 2017. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them.
Key Financial Metrics
The filing does not provide financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively details specific share transactions.
| Transaction Date | Instrument | Price per ADS | Total Volume (ADSs) |
|---|---|---|---|
| April 24, 2017 | GlaxoSmithKline plc ADSs (ISIN: US37733W1053) | $41.1461 | 2,060.699 (Aggregated) |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document reports three separate but identical transactions executed on the same day at the same price, all resulting from dividend reinvestment plans.
Management Commentary and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. The transactions were executed on the New York Stock Exchange (XNYS) following the reinvestment of dividends paid to shareholders on April 13, 2017.
Key Facts for Investor Verification
- Transaction Nature: All reported transactions were acquisitions of ADSs via dividend reinvestment, not open market purchases or sales.
- Executives Involved:
- Mr. N. Hirons (SVP, Global Ethics & Compliance): 19.456 ADSs
- Mr. B. McNamara (CEO, Consumer Healthcare): 230.514 ADSs
- Mr. D. E. Troy (SVP & General Counsel): 1,810.730 ADSs
- Market Price: The execution price for all transactions was $41.1461 per ADS.
- Reporting Limitation: This filing does not contain quarterly or annual financial results; investors should refer to Form 20-F for comprehensive financial data.